The biggest winner in September was Memory Pharmaceuticals (MEMY), which announced that the safety portion of its Phase II trial for Alzheimer’s is complete and the efficacy portion of the trial will now begin (see MEMY, page 4). ACADIA (ACAD) was also up this month on steady progress of their schizophrenia pipeline. NeuroInsights spoke with CEO, Uli Hacksell, and thinks ACADIA is in a good position to continue its upward climb (see ACADIA, page 6). Last month, we highlighted an expected FDA approval announcement on Cephalon (CEPH) and Alkermes (ALKS) alcoholism treatment Vivitrex. CEPH gained throughout the month, and slipped only slightly when investors were dissappointed by a three month FDA delay. Sepracor (SEPR) was up on positive Phase IV Lunesta results showing improved sleep and daytime functioning without a rebound effect when the drug is discontinued (see SEPRACOR, page 4).
